ACADIA Pharmaceuticals/$ACAD

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.

Ticker

$ACAD
Primary listing

Industry

Biotechnology

Employees

654

ISIN

US0042251084

ACAD Metrics

BasicAdvanced
$3.7B
16.23
$1.37
0.48
-

What the Analysts think about ACAD

Analyst ratings (Buy, Hold, Sell) for ACADIA Pharmaceuticals stock.

Bulls say / Bears say

Analysts maintain a 'Buy' rating for ACADIA Pharmaceuticals, with an average price target of $25.56, indicating potential upside from current levels. (etfdailynews.com)
Institutional investors, such as Birchview Capital LP, hold significant positions in ACADIA Pharmaceuticals, reflecting confidence in the company's prospects. (marketbeat.com)
The company's drug, Daybue, approved for treating Rett Syndrome, has the potential to capture a substantial market share in this rare disease segment. (reuters.com)
Culper Research disclosed a short position in ACADIA Pharmaceuticals, citing concerns over Daybue's safety profile and potential patient discontinuations. (reuters.com)
Insider selling activity, including significant stock sales by company executives, may signal a lack of confidence in the company's near-term performance. (etfdailynews.com)
Legal challenges, such as investor lawsuits alleging misleading statements about drug approvals, could negatively impact the company's reputation and financial standing. (bloomberglaw.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

ACAD Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ACAD Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACAD

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs